Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage precision oncology company that reports frequent updates related to its efforts to develop therapies for RAS/MAPK pathway-driven cancers. News about Erasca often centers on progress within its RAS-targeting franchise, including clinical, preclinical, regulatory, and intellectual property developments.
Investors following ERAS news can expect detailed announcements on the advancement of the company’s key product candidates, ERAS-0015 and ERAS-4001. Erasca issues releases on milestones such as investigational new drug (IND) clearances, initiation and progress of Phase 1 trials, and early clinical observations in patients with RAS-mutant and KRAS-mutant solid tumors. The company also reports on patent issuances that extend composition of matter protection for its molecules and on scientific presentations at major oncology and healthcare conferences.
Erasca’s news flow includes quarterly business updates and financial results, typically accompanied by commentary from management on the status of the AURORAS-1 and BOREALIS-1 trials, cash resources, and research and development priorities. The company additionally announces participation in investor conferences hosted by firms such as J.P. Morgan, Evercore, Guggenheim, Stifel, Jefferies, Goldman Sachs, and Morgan Stanley, where its leadership discusses strategy and pipeline progress.
For readers tracking ERAS, this news stream provides insight into how Erasca is advancing its clinical-stage programs targeting RAS and KRAS, how it is building its intellectual property position, and how management frames the opportunities and risks associated with its focus on RAS/MAPK pathway-driven cancers.
Erasca, Inc. (Nasdaq: ERAS) has announced presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 2-6, 2023, in Chicago. The posters will detail preliminary Phase 1b combination data for ERAS-007, a potential best-in-class ERK1/2 inhibitor, in patients with gastrointestinal malignancies. Key presentations include:
- Abstract 3557: Data from ERAS-007 combined with encorafenib and cetuximab in patients with metastatic BRAF V600E mutated colorectal cancer.
- Abstract 3558: Data from ERAS-007 combined with palbociclib in patients with KRAS/NRAS mutated colorectal cancer or KRAS mutated pancreatic ductal adenocarcinoma.
These studies reflect Erasca's commitment to advancing therapies targeting the RAS/MAPK pathway.
Erasca, Inc. (ERAS) recently published preliminary results in the Journal of Clinical Oncology from a Phase 1b study assessing naporafenib and trametinib for NRAS-mutant melanoma. The study reported a promising 47% overall response rate (ORR) and a median progression-free survival (mPFS) of 5.5 months using a preferred dosing regimen. This combination is significant as NRAS mutations affect about 20% of melanoma patients, with no currently approved targeted therapies. Given its higher efficacy compared to standard chemotherapy, which shows an ORR of only 7% and mPFS of 1.5 months, Erasca plans to initiate a pivotal Phase 3 trial (SEACRAFT-2) in H1 2024. The study reinforces the potential of this combination therapy in improving outcomes for patients with NRASm melanoma.
Erasca (Nasdaq: ERAS) announced promising initial results from the Phase 1b FLAGSHP-1 study for its SHP2 inhibitor ERAS-601 combined with cetuximab (ERBITUX) in patients with advanced solid tumors. The combination therapy showed favorable pharmacokinetics, with no significant drug-drug interactions and primarily low-grade adverse events (AEs). The maximum tolerated dose was established at 40 mg BID with a dosing schedule of three weeks on followed by one week off. The company plans to explore efficacy in HPV-negative head and neck squamous cell carcinoma (HNSCC), an area of high unmet medical need, with dose expansion data expected in the first half of 2024. The results support the potential of ERAS-601 as a backbone therapy, aiming to delay therapeutic resistance in cancer treatment.
Erasca, Inc. (Nasdaq: ERAS) announced the promotions of Shannon R. Morris, M.D., Ph.D., to Chief Medical Officer and Chandra D. Lovejoy, M.S., to Chief Regulatory Affairs Officer, effective immediately. Morris succeeds Wei Lin, M.D., who is stepping down. Jonathan E. Lim, M.D., the chairman and CEO, praised both leaders for their integral roles in Erasca's clinical and regulatory achievements, especially with the recent in-licensing of naporafenib. Morris brings over 20 years of oncology experience, having led successful programs at Istari Oncology, G1 Therapeutics, and AstraZeneca. Lovejoy, with two decades in regulatory affairs, has also held pivotal roles in successful drug approvals. The company remains focused on advancing its RAS/MAPK pathway-driven therapies, positioning itself for growth.
Erasca, a clinical-stage oncology company, announced significant developments in its recent press release. The company signed an exclusive worldwide license for naporafenib, a pan-RAF inhibitor, and completed a $100 million equity offering. It plans multiple clinical data readouts throughout 2023, including for its ERAS-007 and ERAS-601 therapies. As of December 31, 2022, Erasca had a robust balance sheet with cash and equivalents totaling $436 million, expected to support operations into H2 2025. However, the company reported a net loss of $242.8 million for the full year 2022, primarily due to in-process R&D expenses associated with the naporafenib licensing agreement.
Erasca Inc. (Nasdaq: ERAS) announced a poster presentation at the AACR Annual Meeting on April 18, 2023, discussing preliminary Phase 1 dose escalation data for ERAS-601, a potential best-in-class SHP2 inhibitor, in combination with cetuximab. This study focuses on advanced or metastatic solid tumors. The poster will be available online post-presentation. The company emphasized its mission to develop therapies targeting RAS/MAPK pathway-driven cancers and highlighted the scientific expertise behind its cancer treatments. Caution is advised regarding forward-looking statements on product efficacy and potential risks in clinical development.
FAQ
What is the current stock price of Erasca (ERAS)?
What is the market cap of Erasca (ERAS)?
